Analyst Ratings for [MRUS] Merus N.V.

2/13/25	Initiated	Overweight	X
MRUS Merus Piper Sandler
$84
2/7/25	Initiated	Overweight	X
MRUS Merus Wells Fargo
$91
11/21/24	Initiated	Buy	X
MRUS Merus Goldman
$73
10/24/24	Initiated	Buy	X
MRUS Merus UBS
$72
3/28/24	Initiated	Buy	X
MRUS Merus Truist
$69
3/4/24	Reiterated	Buy	X
MRUS Merus Needham
$42 $65
11/2/23	Initiated	Buy	X
MRUS Merus Canaccord Genuity
$45
8/21/23	Initiated	Outperform	X
MRUS Merus TD Cowen
8/2/22	Initiated	Buy	X
MRUS Merus Stifel
$38
2/11/22	Initiated	Outperform	X
MRUS Merus BMO Capital Markets
$45
2/10/22	Initiated	Buy	X
MRUS Merus Needham
$45
11/17/21	Resumed	Buy	X
MRUS Merus Guggenheim
$44
6/7/21	Upgrades	Neutral Buy	X
MRUS Merus Citigroup
$24 $31
4/8/21	Initiated	Outperform	X
MRUS Merus William Blair
3/16/21	Initiated	Outperform	X
MRUS Merus SVB Leerink
$33
6/28/19	Initiated	Buy	X
MRUS Merus ROTH Capital
$20
4/12/19	Resumed	Buy	X
MRUS Merus Guggenheim
4/3/19	Upgrades	Sec Perform Outperform	X
MRUS Merus RBC Capital Mkts
3/27/19	Initiated	Buy	X
MRUS Merus Berenberg
$35

MRUS Merus N.V.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.